-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On August 18, Guangzhou Yinming Biomedical Technology Co.
, Ltd.
(hereinafter referred to as "Inming Bio") officially submitted a prospectus to the Hong Kong Stock Exchange on August 17, and the company plans to be listed on the main board
.
According to the data, Yinming Bio is an innovation-driven biopharmaceutical company dedicated to the independent discovery and development of potential First-in-Class, and is committed to solving the major unmet clinical needs in many medical fields around the world
.
The company is mainly engaged in medical research and experimental development (except human stem cells, gene diagnosis and treatment technology); biomedical technology research (except human stem cells, gene diagnosis and treatment technology); drug research and development (except human stem cells, gene diagnosis and treatment technology); Data processing and storage services; data processing and storage product design,
etc.
Due to the rich product line of MingBio, it currently has at least seven self-developed drugs under development, covering four major fields: ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs and pet immune drugs
.
Among them, the small-molecule drug candidate QA102 is the company's core product.
As a potential First-in-Class drug candidate for the treatment of dry age-related macular degeneration, clinical trials have shown that it has good safety and was well tolerated in healthy participants
.
As of August 11, 2022, QA102 has become one of five small molecule drug candidates for dry age-related macular degeneration that have entered Phase II clinical trials in the world
.
The company has stated that QA102 is aimed at dry age-related macular degeneration, a blinding eye disease that currently has no cure in the world, and has huge clinical needs and market prospects
.
The Phase I clinical trial of QA102 in the United States has been successfully concluded, and it is about to officially enter the Phase II clinical trial stage
.
QA108 is an innovative Chinese medicine under development of the company for the treatment of dry age-related macular degeneration.
The product has been approved for drug clinical trials in January 2022 and is currently undergoing Phase II clinical trials in China
.
In addition, Yinming Bio is developing a small-molecule eye drop drug QD109, which can destroy Demodex for the treatment of blepharitis associated with Demodex inflammation)
.
It is reported that the company is preparing a drug clinical trial application for QD109 to start clinical trials in the United States
.
Since 2021, Yinming Bio has submitted and approved 3 drug clinical trial applications to the FDA, and 4 drug clinical trial applications to the State Food and Drug Administration of China.
As of August 11, 2022, 6 of them have been approved.
successfully approved
.
Behind the continuous breakthrough of the company's R&D pipeline, it is inseparable from the support of a strong technical team
.
As of August 11, 2022, Yinming Bio's R&D team includes 169 members, of which 21 team members hold Ph.
D.
and/or MD degrees
.
Its R&D team and scientific committee include domestic and foreign scientists and professionals specializing in oncology, AIDS, ophthalmology, dermatology, botulinum toxin and other fields
.
The potential of the company's existence is also optimistic about the capital
.
It is reported that since its establishment in 2016, Yinming Bio has obtained Qianming Investment, Huacheng Venture Capital, Chengxin Venture Capital, Jingcheng Capital, Gaorong Capital, Lightspeed China, Hengqin Gold Investment, Huajin Capital, Yixian E-commerce, Haisong Capital, Taixin Capital, Jifeng Capital, Yifeng Capital, Nansha Financial Holdings, Taiping Medical and Health and other dozens of large institutions have invested, with a total financing of 900 million yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, Ltd.
(hereinafter referred to as "Inming Bio") officially submitted a prospectus to the Hong Kong Stock Exchange on August 17, and the company plans to be listed on the main board
.
According to the data, Yinming Bio is an innovation-driven biopharmaceutical company dedicated to the independent discovery and development of potential First-in-Class, and is committed to solving the major unmet clinical needs in many medical fields around the world
.
The company is mainly engaged in medical research and experimental development (except human stem cells, gene diagnosis and treatment technology); biomedical technology research (except human stem cells, gene diagnosis and treatment technology); drug research and development (except human stem cells, gene diagnosis and treatment technology); Data processing and storage services; data processing and storage product design,
etc.
Due to the rich product line of MingBio, it currently has at least seven self-developed drugs under development, covering four major fields: ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs and pet immune drugs
.
Among them, the small-molecule drug candidate QA102 is the company's core product.
As a potential First-in-Class drug candidate for the treatment of dry age-related macular degeneration, clinical trials have shown that it has good safety and was well tolerated in healthy participants
.
As of August 11, 2022, QA102 has become one of five small molecule drug candidates for dry age-related macular degeneration that have entered Phase II clinical trials in the world
.
The company has stated that QA102 is aimed at dry age-related macular degeneration, a blinding eye disease that currently has no cure in the world, and has huge clinical needs and market prospects
.
The Phase I clinical trial of QA102 in the United States has been successfully concluded, and it is about to officially enter the Phase II clinical trial stage
.
QA108 is an innovative Chinese medicine under development of the company for the treatment of dry age-related macular degeneration.
The product has been approved for drug clinical trials in January 2022 and is currently undergoing Phase II clinical trials in China
.
In addition, Yinming Bio is developing a small-molecule eye drop drug QD109, which can destroy Demodex for the treatment of blepharitis associated with Demodex inflammation)
.
It is reported that the company is preparing a drug clinical trial application for QD109 to start clinical trials in the United States
.
Since 2021, Yinming Bio has submitted and approved 3 drug clinical trial applications to the FDA, and 4 drug clinical trial applications to the State Food and Drug Administration of China.
As of August 11, 2022, 6 of them have been approved.
successfully approved
.
Behind the continuous breakthrough of the company's R&D pipeline, it is inseparable from the support of a strong technical team
.
As of August 11, 2022, Yinming Bio's R&D team includes 169 members, of which 21 team members hold Ph.
D.
and/or MD degrees
.
Its R&D team and scientific committee include domestic and foreign scientists and professionals specializing in oncology, AIDS, ophthalmology, dermatology, botulinum toxin and other fields
.
The potential of the company's existence is also optimistic about the capital
.
It is reported that since its establishment in 2016, Yinming Bio has obtained Qianming Investment, Huacheng Venture Capital, Chengxin Venture Capital, Jingcheng Capital, Gaorong Capital, Lightspeed China, Hengqin Gold Investment, Huajin Capital, Yixian E-commerce, Haisong Capital, Taixin Capital, Jifeng Capital, Yifeng Capital, Nansha Financial Holdings, Taiping Medical and Health and other dozens of large institutions have invested, with a total financing of 900 million yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
